Journal article
Quality of life in the FOXFIRE, SIRFLOX and FOXFIRE-global randomised trials of selective internal radiotherapy for metastatic colorectal cancer
J Wolstenholme, F Fusco, AM Gray, J Moschandreas, PS Virdee, S Love, G Van Hazel, P Gibbs, HS Wasan, RA Sharma
International Journal of Cancer | WILEY | Published : 2020
DOI: 10.1002/ijc.32828
Abstract
Selective internal radiotherapy (SIRT) is a liver-directed treatment involving the injection of yttrium-90 microspheres into the blood supply of liver tumours. There are very few studies assessing health-related quality of life (HRQOL) in patients treated with SIRT. Patients with liver metastases from colorectal cancer (CRC) were randomised in the FOXFIRE (FFr; ISRCTN83867919), SIRFLOX (SF; NCT00724503) and FOXFIRE-Global (FFrG; NCT01721954) trials of first-line oxaliplatin–fluorouracil (FOLFOX) chemotherapy combined with SIRT versus FOLFOX alone. HRQOL was assessed using the three-level EQ-5D, European Organisation for Research and Treatment of Cancer Quality of Life (EORTC QLQ-C30) and EOR..
View full abstractGrants
Awarded by NIHR Biomedical Research Centre, Royal Marsden NHS Foundation Trust/Institute of Cancer Research
Funding Acknowledgements
The FFr trial was developed by the National Cancer Research Institute Colorectal Clinical Study Group and the NIHR Clinical Research Network and equivalents in devolved nations, and was sponsored by the University of Oxford. The SIRFLOX and FOXFIRE-Global studies were sponsored by Sirtex Technology Pty Ltd. The Centre for Statistics in Medicine, Oxford provided statistical input (supported by Cancer Research UK [grant C5529/A16895]). We thank Georgie Perry and Rhona Atkin for secretarial support. This work was supported by the Bobby Moore Fund of Cancer Research UK (A8971CRUK/07/030) and Sirtex Technology Pty Ltd (FFr, FFrG and SF). A.G. is partly supported by the National Institute for Health Research (NIHR) Biomedical Research Centre, Oxford. The FFrG and SR trials are registered at ClinicalTrials.gov, numbers: NCT01721954 and NCT00724503. The FFr trial is registered at Isrctn.com, number: ISRCTN83867919.